DEB-TACE疗法对肝癌患者的病情控制和生存状况分析  

Analysis of Disease Control and Survival Status of Patients with Liver Cancer Treated with DEB-TACE Therapy

作　　者：韩廷超[1] 王忠[1] 申梦圆 HAN Tingchao;WANG Zhong;SHEN Mengyuan(Nanyang First People's Hospital,Nanyang,473000)

机构地区：[1]河南省南阳市第一人民医院,473000

出　　处：《实用癌症杂志》2025年第4期624-627,共4页The Practical Journal of Cancer

摘　　要：目的探讨经动脉载药微球化疗栓塞(DEB-TACE)疗法对肝癌的疗效。方法选取88例肝癌患者进行研究,采用随机数字表法将88例患者均分为2组[对照组(常规经导管动脉化疗栓塞治疗)、观察组(DEB-TACE治疗)],各44例。观察两组患者的疗效、不良反应、肝功能指标变化以及治疗1年后的生存状况。结果与对照组的客观缓解率(68.18%)、疾病控制率(81.82%)相比,观察组(86.36%、95.45%)均提升,且差异有统计学意义(χ^(2)=4.141,P=0.042、χ^(2)=4.062,P=0.044)。两组不良反应总发生率[14/44(31.82%)vs 15/44(34.09%)]比较,差异不显著(χ^(2)=0.051,P=0.821)。两组治疗前、治疗1个月后的肝功能相关指标比较,差异不显著(P>0.05);两组治疗1个月后的AST水平均显著降低(t=2.343,P=0.024)、(t=2.272,P=0.028),TBIL水平均显著提升(t=2.773,P=0.008)、(t=2.280,P=0.028)。观察组1年生存率高于对照组[90.91%(40/44)vs 72.73%(32/44)],差异显著(χ^(2)=4.889,P=0.027)。结论DEB-TACE疗法对控制肝癌患者病情进展及提升患者1年生存率有积极意义,该治疗方案相对安全。Objective To investigate the efficacy of transarterial drug loaded microsphere chemoembolization(DEB-TACE)in the treatment of hepatocellular carcinoma.Methods A total of 88 patients with liver cancer were selected and divided into 2 groups(the control group(conventional transcatheter arterial chemoembolization)and the observation group(DEB-TACE))with 44 cases in each group by random number table method.The efficacy,adverse reactions,changes of liver function indexes and survival status 1 year after treatment were observed in the two groups.Results Compared with the control group,the objective remission rate(68.18%)and disease control rate(81.82%)in the observation group(86.36%and 95.45%)were both improved,and the differences were statistically significant(χ^(2)=4.141,P=0.042,χ^(2)=4.062,P=0.044).There was no significant difference in the overall incidence of adverse reactions between the 2 groups[14/44(31.82%)vs 15/44(34.09%)](χ^(2)=0.051,P=0.821).There was no significant difference in liver function related indexes between the two groups before treatment and after 1 month of treatment(P>0.05),AST level was significantly decreased(t=2.343,P=0.024)and(t=2.272,P=0.028)after 1 month of treatment in both groups,and TBIL level was significantly increased(t=2.773,P=0.008,t=2.280,P=0.028).The 1-year survival rate of observation group was higher than that of control group[90.91%(40/44)vs 72.73%(32/44)],and the difference was significant(χ^(2)=4.889,P=0.027).Conclusion DEB-TACE therapy has positive significance in controlling the progression of liver cancer patients and improving the 1-year survival rate of patients,and the treatment is relatively safe.

关 键 词：DEB-TACE 肝癌 疗效 疾病控制 肝功能 生存状况 

分 类 号：R735.7[医药卫生—肿瘤]